9 Words From Moderna's CEO That Could Signal a Boost in Vaccine Orders
One big concern has preoccupied vaccine stock investors over the past few weeks: the possibility that vaccine sales will taper off as the pandemic wanes. Shares of vaccine leader Moderna (NASDAQ: MRNA) slipped in early November after the biotech cut this year's sales forecast. Even though it didn't have to do with a loss of orders, investors still worried.
Of course, experts say the coronavirus is here to stay. So it's logical to assume we'll still need vaccination to protect us. But it's also logical to assume that the world may not move to vaccinate as quickly and aggressively once the pandemic is over. That opens the door to the idea of smaller vaccine orders. So, what's an investor to think? Let's look at a clue directly from Moderna's CEO.
Image source: Getty Images.
Source Fool.com